Table 3 Treatment-related adverse events
TRAEs | All grades n (%) | Grade 3–4 n (%) |
|---|---|---|
Any grade | 42 (91.3) | 5 (10.9) |
Grade 3 | 3 (6.5) | |
Grade 4 | 2 (4.3) | |
SAE | 5 (10.9) | 3 (6.5) |
TRAEs leading to death | 0 | 0 |
TRAEs leading to treatment discontinuation | 2 (4.3) | 2 (4.3) |
≥10% TRAEs | ||
Anemia | 15 (32.6) | 0 |
Elevated α-hydroxybutyrate dehydrogenase | 13 (28.3) | 0 |
Elevated alanine aminotransferase | 12 (26.1) | 0 |
Elevated aspartate aminotransferase | 10 (21.7) | 0 |
Elevated blood lactate dehydrogenase | 10 (21.7) | 0 |
Decreased serum albumin | 9 (19.6) | 0 |
Elevated blood glucose | 9 (19.6) | 0 |
Decreased platelet count | 7 (15.2) | 0 |
Elevated γ-glutamyl transferase | 6 (13.0) | 0 |
Decreased white blood cell count | 6 (13.0) | 1 (2.2) |
Decreased thyrotropin stimulating hormone | 6 (13.0) | 0 |
Elevated creatine kinase (MB form) | 6 (13.0) | 0 |
Elevated creatine kinase | 6 (13.0) | 0 |
Lacking in strength | 6 (13.0) | 0 |
Elevated serum creatinine | 5 (10.9) | 0 |
Elevated free thyroxine | 5 (10.9) | 0 |
